These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24877124)

  • 1. The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.
    Kim IY; Lee DW; Lee SB; Kwak IS
    Biomed Res Int; 2014; 2014():638732. PubMed ID: 24877124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Effects of Hyperuricemia.
    Méndez Landa CE
    Contrib Nephrol; 2018; 192():8-16. PubMed ID: 29393089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperuricemia and chronic kidney disease: to treat or not to treat.
    Piani F; Sasai F; Bjornstad P; Borghi C; Yoshimura A; Sanchez-Lozada LG; Roncal-Jimenez C; Garcia GE; Hernando AA; Fuentes GC; Rodriguez-Iturbe B; Lanaspa MA; Johnson RJ
    J Bras Nefrol; 2021; 43(4):572-579. PubMed ID: 33704350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease.
    Ryu ES; Kim MJ; Shin HS; Jang YH; Choi HS; Jo I; Johnson RJ; Kang DH
    Am J Physiol Renal Physiol; 2013 Mar; 304(5):F471-80. PubMed ID: 23283992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of uric acid in inflammasome-mediated kidney injury.
    Braga TT; Foresto-Neto O; Camara NOS
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):423-431. PubMed ID: 32452918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol, uric acid, and oxidative stress in cardiorenal disease.
    Riegersperger M; Covic A; Goldsmith D
    Int Urol Nephrol; 2011 Jun; 43(2):441-9. PubMed ID: 21547469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid as a target of therapy in CKD.
    Jalal DI; Chonchol M; Chen W; Targher G
    Am J Kidney Dis; 2013 Jan; 61(1):134-46. PubMed ID: 23058478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
    Kosugi T; Nakayama T; Heinig M; Zhang L; Yuzawa Y; Sanchez-Lozada LG; Roncal C; Johnson RJ; Nakagawa T
    Am J Physiol Renal Physiol; 2009 Aug; 297(2):F481-8. PubMed ID: 19458127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for uric acid in the progression of renal disease.
    Kang DH; Nakagawa T; Feng L; Watanabe S; Han L; Mazzali M; Truong L; Harris R; Johnson RJ
    J Am Soc Nephrol; 2002 Dec; 13(12):2888-97. PubMed ID: 12444207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperuricemia and xanthine oxidase in preeclampsia, revisited.
    Many A; Hubel CA; Roberts JM
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):288-91. PubMed ID: 8572024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uric acid and progression of chronic kidney disease.
    Weaver DJ
    Pediatr Nephrol; 2019 May; 34(5):801-809. PubMed ID: 29931555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
    Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S
    Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The uric acid cardio-nephropathy].
    Viazzi F; Bonino B; Cappadona F; Pontremoli R
    G Ital Nefrol; 2017 Mar; 34(Suppl 69):41-48. PubMed ID: 28682028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
    Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H
    J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis.
    Wang Y; Kong W; Wang L; Zhang T; Huang B; Meng J; Yang B; Xie Z; Zhou H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33080936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
    Kim HS; Lim SW; Jin L; Jin J; Chung BH; Yang CW
    Nephron; 2017; 135(1):61-71. PubMed ID: 27701176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
    Ohya M; Shigematsu T
    Clin Exp Nephrol; 2014 Dec; 18(6):835-6. PubMed ID: 24871070
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperuricemia and endothelial function: From molecular background to clinical perspectives.
    Maruhashi T; Hisatome I; Kihara Y; Higashi Y
    Atherosclerosis; 2018 Nov; 278():226-231. PubMed ID: 30326405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia.
    Kim YJ; Oh SH; Ahn JS; Yook JM; Kim CD; Park SH; Cho JH; Kim YL
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
    Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
    Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.